RefleXion Medical Stock
The first biologically-guided radiation therapy for cancer.
About RefleXion Medical Stock
RefleXion Medical is a privately held medical device company developing the first biology-guided radiation therapy system for cancer treatment. By leveraging Positron Emission Tomography (PET) in a novel way, RefleXion's patented technology will allow tumors to continuously signal their location during treatment and potentially revolutionize the practice of radiation oncology. Early validation of RefleXion's technology was funded by the National Cancer Institute. RefleXion is backed by premier investors; Sofinnova Partners, KCK, Pfizer, Venrock and Johnson & Johnson Innovation.
Investors
Sofinnova Partners
The Rise Fund
Funding History
| April 2014 | $11.7M |
|---|---|
| April 2016 | $52.1M |
| March 2018 | $103M |
Management
Founder and CTO
Sam Mazin
President & CEO
Todd Powell
Principal UX Engineer
Michael Owens
Vice President of Engineering
David Larkin
Senior Director - Product
Cal Huntzinger
VP, Regulatory/Clinical/QA
Kathy O’Shaughnessy
Founder and VP of Business Development
Akshay Nanduri
Press
Imaging Technology News (press release) (blog) - Nov, 8 2018
DOTmed.com - Oct, 24 2018
Associated Press (press release) (blog) - Oct, 18 2018
GlobeNewswire (press release) - Oct, 18 2018
GlobeNewswire (press release) - Oct, 15 2018
PR Newswire (press release) - Oct, 15 2018
PR Newswire (press release) - Aug, 27 2018
DOTmed.com - Apr, 11 2018
GlobeNewswire (press release) - Apr, 4 2018
FierceBiotech - Sep, 25 2017
Marketwired (press release) - May, 8 2017
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from RefleXion Medical or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
